Table 2.
Univariate Analysis of Facter Associated the Incidence of Grade 3 or Higher Thrombocytopenia to Patients Received DeVIC Therapy
| Odds ratio | 95% CI | P-value | |
|---|---|---|---|
| Platelet count before administration (×104 /μL) | 0.95 | 0.90-1.00 | 0.1 |
| Body surface area (m2) | 0.1 | 0.001-8.66 | 0.3 |
| Ccr before administration (mL/min) | 0.97 | 0.93-1.01 | 0.15 |
| Age (years) | 0.95 | 0.86-1.05 | 0.28 |
| Sex, male | 0.94 | 0.23-3.92 | 0.94 |
| Treatment line | 1.37 | 0.87-2.17 | 0.17 |
| AUC actual | 1.05 | 1.00-1.10 | 0.02 |
| Ifosfamide dose (mg/m2) | 1 | 1.00-1.00 | 0.08 |
| Etoposide dose (mg/m2) | 1.04 | 0.99-1.09 | 0.11 |
| LDH | 1 | 0.99-1.01 | 0.08 |
| With rituximab | 1.53 | 0.37-6.35 | 0.56 |
Abbreviation: confidence interval; CI, creatinine clearance; Ccr, area under the curve; AUC, AUC estimated from the actual carboplatin dose; AUC actual